Genenta Science S.p.A. Logo

Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):
US36870W1009
LEI:
Country:
United States of America
Address:
OLGETTINA, NO. 58, 20132 MILAN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Evolus, Inc. Logo
Develops neurotoxins and dermal fillers for the medical aesthetics market.
United States of America EOLS
EXACT SCIENCES CORP Logo
Provides advanced cancer screening and diagnostic tests for early detection and treatment guidance.
United States of America EXAS
EXELIXIS, INC. Logo
An oncology-focused biotech that discovers and develops medicines for hard-to-treat cancers.
United States of America EXEL
EXICURE, INC. Logo
Develops nucleic acid therapies via its SNA™ platform for neurology, oncology, & genetic diseases.
United States of America XCUR
ExpreS2ion Biotech Holding AB Logo
Clinical-stage biotech developing vaccines and immunotherapies via a proprietary protein platform.
Sweden EXPRS2
EyeGene,Inc Logo
Develops gene/cell therapies & mRNA vaccines for age-related and ocular diseases.
South Korea 185490
EyePoint Pharmaceuticals, Inc. Logo
Develops innovative, sustained-delivery therapeutics for retinal diseases.
United States of America EYPT
Faes Farma S.A. Logo
Develops and markets pharmaceuticals, like antihistamines, and animal nutrition products globally.
Spain FAE
Fagron N.V. Logo
Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.
Belgium FAGR
Farmak Logo
A pharmaceutical manufacturer and exporter of 400+ medicines to over 50 countries.
Ukraine FARM

Talk to a Data Expert

Have a question? We'll get back to you promptly.